Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JADE NASDAQ:PRIM NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJADELJ International$54.64+0.1%$0.00$0.00▼$0.00N/AN/AN/A85 shsPRIMPrimoris Services$87.45+2.3%$76.99$45.92▼$90.86$4.72B1.37785,476 shs860,090 shsTERNTerns Pharmaceuticals$5.60+6.3%$3.78$1.87▼$11.40$460.27M-0.111.45 million shs1.81 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJADELJ International+0.91%+0.48%+3.16%+18.81%+11.52%PRIMPrimoris Services-0.86%+1.14%+12.67%+51.64%+61.33%TERNTerns Pharmaceuticals+4.36%+7.77%+31.42%+119.13%-45.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJADELJ InternationalN/AN/AN/AN/AN/AN/AN/AN/APRIMPrimoris Services4.0497 of 5 stars1.43.01.73.23.52.51.9TERNTerns Pharmaceuticals3.8618 of 5 stars3.31.00.04.12.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJADELJ International 0.00N/AN/AN/APRIMPrimoris Services 2.89Moderate Buy$90.223.18% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63179.02% UpsideCurrent Analyst Ratings BreakdownLatest TIR, JADE, TERN, and PRIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025PRIMPrimoris ServicesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.007/16/2025PRIMPrimoris ServicesKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$79.00 ➝ $98.007/3/2025PRIMPrimoris ServicesJanney Montgomery ScottSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$102.005/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.005/7/2025PRIMPrimoris ServicesKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $74.005/7/2025PRIMPrimoris ServicesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$75.00 ➝ $76.004/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJADELJ InternationalN/AN/AN/AN/AN/AN/APRIMPrimoris Services$6.60B0.72$6.33 per share13.82$23.17 per share3.77TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJADELJ InternationalN/AN/A0.00∞N/AN/AN/AN/AN/APRIMPrimoris Services$126.14M$3.7828.9621.59N/A2.68%15.23%4.88%8/4/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)Latest TIR, JADE, TERN, and PRIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025N/APRIMPrimoris Services$1.10N/AN/AN/A$1.69 billionN/A8/4/2025Q2 2025TERNTerns Pharmaceuticals-$0.29N/AN/AN/AN/AN/A5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A5/5/2025N/APRIMPrimoris Services$0.70$0.98+$0.28N/A$1.49 billion$1.65 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJADELJ InternationalN/AN/AN/AN/AN/APRIMPrimoris Services$0.320.37%N/A8.47%1 YearsTERNTerns PharmaceuticalsN/AN/AN/AN/AN/ALatest TIR, JADE, TERN, and PRIM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/6/2025PRIMPrimoris Servicesquarterly$0.080.5%6/30/20256/30/20257/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJADELJ InternationalN/AN/AN/APRIMPrimoris Services0.611.381.38TERNTerns PharmaceuticalsN/A30.8930.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJADELJ InternationalN/APRIMPrimoris Services91.82%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipJADELJ InternationalN/APRIMPrimoris Services0.90%TERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJADELJ InternationalN/AN/AN/ANot OptionablePRIMPrimoris Services12,80054.00 million52.96 millionOptionableTERNTerns Pharmaceuticals4087.34 million86.03 millionNot OptionableTIR, JADE, TERN, and PRIM HeadlinesRecent News About These CompaniesObesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-WaitingJuly 14 at 10:35 AM | biospace.comBTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $15.63 Average Price Target from AnalystsJuly 12, 2025 | americanbankingnews.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 9, 2025 | marketbeat.comTerns Pharmaceuticals CEO & Director Acquires 98% More StockJuly 4, 2025 | finance.yahoo.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Purchases $39,300.00 in StockJune 30, 2025 | marketbeat.comTerns pharmaceuticals CEO Burroughs buys $90k in sharesJune 27, 2025 | investing.comRivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potentialJune 26, 2025 | fiercebiotech.comFInsider Buying: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Buys 23,314 Shares of StockJune 25, 2025 | marketbeat.comTerns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - NasdaqJune 24, 2025 | nasdaq.comTerns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - MorningstarJune 24, 2025 | morningstar.comMNovel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly DosingJune 23, 2025 | medpagetoday.comMTerns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific SessionsJune 23, 2025 | globenewswire.comPopulation-Level Weight Loss Seen With Primary Care ProtocolJune 21, 2025 | medscape.comMSG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)June 18, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Buys $19,750.00 in StockJune 17, 2025 | insidertrades.comNASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsightJune 13, 2025 | theglobeandmail.com3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comTerns Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 29, 2025 | globenewswire.comTerns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potentialMay 27, 2025 | investing.comTerns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701May 14, 2025 | globenewswire.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%May 10, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the Start3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedTIR, JADE, TERN, and PRIM Company DescriptionsLJ International NASDAQ:JADELJ International Inc. (LJI) is a holding company. The Company is a vertically integrated jewelry company that designs, brands, markets, distributes and retails a complete range of fine jewelry through retail and wholesale channels. The Company specializes in colored gemstone jewelry and also offers jewelry set in yellow gold, white gold or sterling silver, as well as diamond. The Company's product lines include earrings, necklaces, pendants, rings and bracelets. The Company conducts its retail jewelry business through the ENZO brand in the Asia Pacific region, with a primary focus in the China market. The Company operates in two segments: manufacture and wholesale of jewelry products, and retail of jewelry products. In July 2013, LJ International Inc announced the completion of the merger. As a result of the merger, the Company became a wholly owned subsidiary of Flora Bloom Holdings.Primoris Services NASDAQ:PRIM$87.44 +1.95 (+2.27%) Closing price 03:59 PM EasternExtended Trading$87.46 +0.02 (+0.02%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Primoris Services Corporation, a specialty contractor company, provides a range of specialty construction, fabrication, maintenance, replacement, and engineering services in the United States and Canada. The company operates through Utilities and Energy/Renewables segments. The Utilities segment offers installation and maintenance services for new and existing natural gas distribution systems, electric utility distribution and transmission systems, and communications systems. The Energy/Renewables segment provides a range of services, including engineering, procurement, and construction, as well as retrofits, highway and bridge construction, demolition, site work, soil stabilization, excavation, flood control, upgrades, repairs, outages, and maintenance services to renewable energy and energy storage, renewable fuels, petroleum, and petrochemical industries, as well as state departments of transportation. It also offers pipeline construction and maintenance, and storage services; pipeline facility, and integrity services. Primoris Services Corporation was founded in 1960 and is headquartered in Dallas, Texas.Terns Pharmaceuticals NASDAQ:TERN$5.60 +0.33 (+6.26%) Closing price 04:00 PM EasternExtended Trading$5.57 -0.03 (-0.54%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
